Biotech Values

[DewDiligence]

MNTA—Is $150-200M upfront for 3-4 [FoB] compounds initially with options for others [reasonable]?

Four FoB compounds is probably too many to take on at once, even with a big-name partner; two or possibly three compounds is more realistic, IMO.

In regards to M118, do you still think a deal somewhere in $50-75M upfront would be reasonable?

That sounds wildly optimistic considering the length of time the program has been lying fallow. Consistent with the comments in #msg-57621347, if an M118 partnership is not announced in the next month or so, I will ascribe zero value to the program.